Lidamitol, 100 mg/ml +2, 5 mg/ml 1 ml 5 pcs

Tolperisone hydrochloride is a central myorelaxant. The exact mechanism of action is unknown. As a result of membrane-stabilizing action, it interferes with the conduction of excitation in primary afferent fibers, blocking mono- and polysynaptic reflexes of the spinal cord. Probably the secondary mechanism of action is to block the release of the transmitter by blocking the entry of calcium ions into the synapses.

Decreases reflex readiness in the reticulospinal pathways of the brainstem.

It enhances peripheral blood flow. This action is not related to the effects of the drug on the central nervous system and may be due to the mild antispasmodic and antiadrenergic effects of tolperisone.

Lidocaine hydrochloride has a local anesthetic effect and has no systemic action when dosed by Lidamy Gol according to the instructions.

Indications

– Symptomatic treatment of spasticity in adults due to stroke.

– Treatment of painful muscle spasms associated with diseases of the musculoskeletal system (spondylosis, spondyloarthrosis, cervical and lumbar syndromes).

Pharmacological effect

Tolperisone hydrochloride is a central muscle relaxant. The exact mechanism of action is unknown. As a result of the membrane-stabilizing effect, it prevents the conduction of excitation in primary afferent fibers, blocking mono- and polysynaptic reflexes of the spinal cord. It is likely that the secondary mechanism of action is to block transmitter release by blocking the entry of calcium ions into synapses.

Reduces reflex readiness in the reticulospinal tracts of the brain stem.

Strengthens peripheral blood circulation. This action is not associated with the effect of the drug on the central nervous system and may be due to the weak antispasmodic and antiadrenergic effect of tolperisone.

Lidocaine hydrochloride has a local anesthetic effect and does not have a systemic effect when dosed with Lidami Gol according to the instructions.

Active ingredient

Tolperisone, [Lidocaine]

Composition

1 ml of the drug contains:

Active ingredients:

Tolperisone hydrochloride 100 mg

Lidocaine hydrochloride monohydrate (in terms of lidocaine hydrochloride) 2.5 mg

Excipients:

Methyl parahydroxybenzoate 0.6 mg

Propylene glycol 0.3 ml

1 M hydrochloric acid solution to pH 3.0-4.5

Water for injections up to 1 ml.

Contraindications

Hypersensitivity to any of the components of the drug (including lidocaine), myasthenia gravis, children under 18 years of age, pregnancy, lactation (due to lack of data).

With caution:

The drug should be used with caution in patients with renal and hepatic insufficiency. No dose adjustment is required.

Side Effects

Classification of the incidence of side effects recommended by the World Health Organization (WHO): very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10000 and <1/1000), very rare (<1/10000), frequency unknown (cannot be estimated based on available data). data).

Disorders of the blood and lymphatic system: very rarely – anemia, lymphadenopathy.

Immune system disorders: rarely – hypersensitivity reactions, anaphylactic reactions; very rarely – anaphylactic shock.

Metabolic and nutritional disorders: infrequently – anorexia; very rarely – polydipsia.

Mental disorders: infrequently – insomnia, sleep disorders; rarely – loss of activity, depression.

Nervous system disorders: uncommon – headache, dizziness, drowsiness; rarely – attention deficit disorder, tremor, convulsions, loss of sensitivity, sensory disorders, lethargy.

Violations of the organ of vision: rarely – disturbances of visual perception.

Hearing and labyrinthine disorders: rarely – tinnitus, vertigo.

Cardiac disorders: rarely – angina pectoris, tachycardia, rapid heartbeat; very rarely – bradycardia.

Vascular disorders: infrequently – arterial hypotension; rarely – flushes of blood.

Respiratory system disorders. organs of the chest and mediastinum: rarely – shortness of breath, nosebleeds, rapid breathing.

Gastrointestinal disorders: uncommon – gastrointestinal discomfort, diarrhea, dry mouth, dyspepsia, nausea; rarely – epigastric pain, constipation, flatulence, vomiting.

Disorders of the liver and biliary tract: rarely – liver dysfunction.

Disorders of the skin and subcutaneous tissues: rarely – allergic dermatitis, sweating, itching, urticaria, skin rash.

Musculoskeletal and connective tissue disorders: uncommon – muscle weakness, myalgia, pain in the extremities; rarely – discomfort in the limbs; very rarely – osteopenia.

Renal and urinary tract disorders: rarely – enuresis, proteinuria.

General disorders and disorders at the injection site: often – redness of the injection site; infrequently – asthenia (weakness), malaise, fatigue; rarely – a feeling of intoxication, a feeling of heat, irritability, thirst; very rarely – a feeling of discomfort in the chest.

Laboratory and instrumental data: rarely – decreased blood pressure, increased bilirubin concentration, impaired liver function tests, decreased platelet count, increased leukocyte count; very rarely – increased creatinine levels.

Interaction

There is no data on interactions with drugs that limit the use of the drug.

Overdose

Symptoms: ataxia, tonic and clonic convulsions, dyspnea and respiratory arrest.

Treatment: symptomatic and supportive therapy is recommended. There is no specific antidote.

Recommendations for use

Adults daily: 1 ml 2 times a day intramuscularly or 1 ml 1 time a day intravenously.

Procedure for working with a polymer ampoule:

1. Take the ampoule and shake it, holding it by the neck.

2. Using a rotating motion, turn and separate the valve from the ampoule.

3. Immediately connect the syringe luer to the ampoule through the resulting hole.

4. Draw the contents of the ampoule into the syringe.

5. Place the needle on the syringe.

Functional features

Tolperisone hydrochloride undergoes intensive metabolism in the liver and kidneys. It is excreted by the kidneys, almost exclusively (> 99%) in the form of metabolites, the pharmacological activity of which is unknown. When administered intravenously, the half-life is about 1.5 hours.

Lidocaine hydrochloride is completely absorbed (the rate of absorption depends on the injection site and dose). The time to reach maximum concentration when administered intramuscularly is 30-45 minutes. Communication with plasma proteins – 50-80%. Quickly distributed in tissues and organs. Penetrates the blood-brain barrier and placental barrier, secreted into breast milk (40% of the concentration in maternal plasma). Metabolized in the liver (90-95%) with the participation of microsomal enzymes by dealkylation of the amino group and cleavage of the amide bond with the formation of active metabolites. Excreted with bile (part of the dose is reabsorbed in the gastrointestinal tract) and kidneys (up to 10% unchanged).

Storage conditions

Store at a temperature not exceeding 15 °C. Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiration date!

Manufacturer

Grotex LLC, Russia